129 MET ECD shedding and poor DFS Supplementary table 14: Cross tabulation showing the number and percentage of MET post-translational status per pathological cancer stage. Pathological cancer stage*, ** No MET Decoy MET Transmembranous C-terminal MET Total # % # % # % # % I 2 14.3 1 7.1 11 78.6 14 100 II 5 16.7 3 10.0 22 73.3 30 100 III 6 18.2 2 6.1 25 75.8 33 100 IV 22 28.6 8 10.4 47 61.0 77 100 Non-parametric testing: P>0.05 * Based on pTNM, which was assessed according to the 7th edition of the AJCC. ** There 2 missing values for pathological cancer stage. Supplementary table 15: Cross tabulation showing the number and percentage of MET shedding status per pathological cancer stage for C-terminal MET positive cancers. Pathological cancer stage*, ** # No shedding Shedding Total # % # % # % I 6 54.5 5 45.5 11 100 II 15 68.2 7 31.9 22 100 III 20 80.0 5 20.0 25 100 IV 27 57.4 20 42.6 47 100 Non-parametric testing: P>0.05 * Based on pTNM, which was assessed according to the 7th edition of the AJCC. ** There was 1 missing value for pathological cancer stage. 4
RkJQdWJsaXNoZXIy MTk4NDMw